CareLit · DOI-Nachweis · Pneumologie
12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection
DOI 10.1055/s-0036-1592232
Bibliografische Angaben
Nachweis in CareLit
Autor:innenK Olivier, D Griffith, K Winthrop, B Brown-Elliott, G Eagle, J McGinnis, R Wallace
ZeitschriftPneumologie
Ausgabe10/2016
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: TR02 – 112 enrolled adult patients with NTM lung infection due to MAC and/or Mycobacterium abscessus refractory to a multi-drug regimen for ≥6 months. The randomized, placebo-controlled study evaluated efficacy, safety, and tolerability of LAI 590 mg administered once daily added to multi-drug regimen for 84 days (Double-blind). Patients continuing in the Open-label phase received LAI added to multi-dr…
Zitieren
Zitierempfehlung
K Olivier, D Griffith, K Winthrop, B Brown-Elliott, G Eagle, J McGinnis, R Wallace (2016) 12-Month Follow-up From Phase 2 Trial of Liposomal Amikacin for Inhalation (LAI) in Patients With Nontuberculous Mycobacterial (NTM) Lung Infection. Pneumologie (10). https://doi.org/10.1055/s-0036-1592232
Mit CareLit weiterarbeiten